InsiderTrades.com logo

LPCN Insider Trading

Insider Ownership Percentage: 6.35%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Lipocine Insider Trading History Chart

This chart shows the insider buying and selling history at Lipocine by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lipocine Share Price & Price History

Current Price: $9.43
Price Change: ▼ Price Decrease of -0.07 (-0.74%)
As of 02/24/2026 05:00 PM ET

This chart shows the closing price history over time for LPCN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Lipocine Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2023Mahesh V. PatelCEOBuy8,706$5.03$43,791.18107,418View SEC Filing Icon  
3/24/2023Mahesh V. PatelCEOBuy8,823$5.44$47,997.1298,711View SEC Filing Icon  
3/20/2023Richard Dana OnoDirectorBuy235$5.78$1,358.30830View SEC Filing Icon  
3/17/2023Mahesh V. PatelCEOBuy2,941$5.61$16,499.0189,887View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Lipocine (NASDAQ:LPCN)

9.11% of Lipocine stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LPCN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lipocine Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Ikarian Capital LLC199,542$1.60M0.1%N/A3.595%Search for SEC Filing on Google Icon
2/18/2026Squadron Capital Management LLC530,000$4.26M1.8%N/A9.550%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC54,893$0.44M0.0%N/A0.989%Search for SEC Filing on Google Icon
2/17/2026Diadema Partners LP260,939$2.10M0.4%N/A4.702%Search for SEC Filing on Google Icon
2/17/2026Persistent Asset Partners Ltd70,576$0.57M0.3%N/A1.272%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC10,574$85K0.0%N/A0.191%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC37,397$0.30M0.0%+3.6%0.674%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC62,450$0.50M0.0%+2.2%1.125%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC14,247$41K0.0%N/A0.257%Search for SEC Filing on Google Icon
11/12/2025Dimensional Fund Advisors LP12,140$35K0.0%-49.1%0.219%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC36,032$0.18M0.0%-10.7%0.673%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC57,464$0.28M0.0%+6.0%1.074%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC25,697$0.21M0.0%+21.8%0.480%Search for SEC Filing on Google Icon
8/9/2024Dimensional Fund Advisors LP11,870$98K0.0%N/A0.222%Search for SEC Filing on Google Icon
1/29/2024Wealth Effects LLC14,639$41K0.0%-22.0%0.275%Search for SEC Filing on Google Icon
10/16/2023Wealth Effects LLC18,761$56K0.0%-35.9%0.353%Search for SEC Filing on Google Icon
7/18/2023Wealth Effects LLC29,273$0.15M0.1%-96.1%0.563%Search for SEC Filing on Google Icon
6/5/2023EP Wealth Advisors LLC66,983$13.40M0.2%N/A1.288%Search for SEC Filing on Google Icon
5/4/2023Wealth Effects LLC756,674$0.24M0.1%-35.8%0.855%Search for SEC Filing on Google Icon
2/13/2023Wealthspan Partners LLC73,950$29K0.0%N/A0.084%Search for SEC Filing on Google Icon
2/2/2023Wealth Effects LLC1,178,834$0.47M0.3%-3.0%1.332%Search for SEC Filing on Google Icon
2/2/2023Bailard Inc.82,957$32K0.0%N/A0.094%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC93,411$42K0.0%N/A0.106%Search for SEC Filing on Google Icon
8/3/2022Carson Advisory Inc.52,000$42K0.0%N/A0.059%Search for SEC Filing on Google Icon
7/27/2022Bailard Inc.74,400$60K0.0%N/A0.084%Search for SEC Filing on Google Icon
7/22/2022Aaron Wealth Advisors LLC145,045$0.12M0.0%+23.4%0.164%Search for SEC Filing on Google Icon
5/13/2022EAM Investors LLC657,804$0.90M0.2%N/A0.743%Search for SEC Filing on Google Icon
5/10/2022Aaron Wealth Advisors LLC117,552$85.81M1.2%N/A0.133%Search for SEC Filing on Google Icon
4/26/2022Kestra Advisory Services LLC307,300$0.42M0.0%+27.9%0.347%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP440,432$0.44M0.1%+39.7%0.499%Search for SEC Filing on Google Icon
2/9/2022Wealth Effects LLC1,489,434$1.48M0.6%N/A1.687%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lipocine logo
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Read More on Lipocine

Today's Range

Now: $9.43
Low: $9.25
High: $9.97

50 Day Range

MA: $8.30
Low: $3.67
High: $11.26

52 Week Range

Now: $9.43
Low: $2.52
High: $12.37

Volume

194,887 shs

Average Volume

135,558 shs

Market Capitalization

$52.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Who are the major institutional investors of Lipocine?

Lipocine's top institutional shareholders include:
  1. Squadron Capital Management LLC — 9.55%
  2. Diadema Partners LP — 4.70%
  3. Ikarian Capital LLC — 3.60%
  4. Persistent Asset Partners Ltd — 1.27%
  5. Geode Capital Management LLC — 1.13%
  6. Boothbay Fund Management LLC — 0.99%
Learn More about top institutional investors of Lipocine stock.

Which institutional investors are buying Lipocine stock?

In the previous quarter, LPCN stock was acquired by institutional investors including:
  1. Squadron Capital Management LLC
  2. Diadema Partners LP
  3. Ikarian Capital LLC
  4. Persistent Asset Partners Ltd
  5. Boothbay Fund Management LLC
  6. Jane Street Group LLC
  7. Geode Capital Management LLC
  8. Renaissance Technologies LLC